机构地区:[1]泸州医学院附属医院整形外科,四川省泸州市646000 [2]中国医学科学院中国协和医科大学整形外科医院,北京市100041
出 处:《中国组织工程研究与临床康复》2007年第3期587-591,共5页Journal of Clinical Rehabilitative Tissue Engineering Research
基 金:四川省应用基础研究计划项目(2006J13-128)~~
摘 要:背景:骨形成蛋白与骨、软骨、肌腱、韧带等多种组织的形成有关,血管内皮细胞生长因子通过提高血管的通透性和促进内皮细胞迁移可促进血管生成。目的:构建人骨形成蛋白2和人血管内皮细胞生长因子165的真核共表达载体,并观察其在骨髓间充质干细胞中的表达。设计:观察对比实验。单位:泸州医学院附属医院整形外科和中国医学科学院中国协和医科大学整形外科医院。材料:骨髓间充质干细胞来源于健康成人献髓志愿者。pIRES-EGFP-hVEGF165含人血管内皮细胞生长因子165全长cDNA序列,由中国医学科学院整形外科医院成挺博士提供。含人全长骨形成蛋白2cDNA序列的克隆载体pSP65-hBMP2,由军事医学科学院基础医学研究所郭希民博士提供。真核表达载体pIRESneo(Clontech公司)Pyrobest DNA Polymerase、限制性内切酶、DNA连接酶和质粒提取试剂盒、DNA片段分离及纯化试剂盒(大连宝生物公司),Lipofec-tamineTM脂质体转染试剂盒、DMEM培养基、胰蛋白酶、TRIzol RNA提取试剂盒(Gibco BRL),Omniscript RT试剂盒(Qiagen),Taqplus-DNA聚合酶(Promega),PMSF、leupeptin、aprotinin、chymostatin(Sig-ma),蛋白酶抑制剂、PVDF膜(Amersham-Pharmacia Biotech),兔抗人BMP2和VEGF单克隆抗体(Santa Cruz公司),羊抗兔IgG-过氧化物酶(博士德公司),G418(美国Ameresco公司)。方法:实验于2005-06/2006-04在泸州医学院附属医院和中国医学科学院中国协和医科大学整形外科医院完成。利用重组DNA和基因克隆技术将人骨形成蛋白2和人血管内皮细胞生长因子165cDNA定向克隆到载体pIRESneo的多克隆位点构建重组质粒,经Xho I/Bgl II双酶切和基因测序鉴定后,在阳离子脂质体介导下转染骨髓间充质干细胞,根据观察结果的需要,将转染的细胞分为IRES-hBMP2-VEGF165组,pIRES-hBMP2组,pIRES-VEGF165组,空质粒对照组,分别给予pIRES-hBMP2-VEGF165,pIRES-hBMP2,pIRES-VEGF165及pIRES-neo转染,取同�BACKGROUND : Bone morphogenetic proteins (BMPs) are involved in the formation of various tissues including bone, cartilage, tendon, and ligament. Vascular endothelial growth factor (VEGF) promotes angiogenesis by increasing the permeability and migration of endothelial cells. OBJECTIVE: To construct a co-expressing vector of human bone morphogenetic protein 2 (BMP2) and vascular endothelial growth factor 165 (VEGF165), and observe the expression of BMP2 and VEGF165 in human bone marrow mesenchymal stem cells (hBMSCs). DESIGN : Observation control trail SETFING: Department of Plastic Surgery, Affiliated Hospital of Luzhou Medical College and Plastic Surgery Hospital of Peking Union Medical College, Chinese Academy of Medical Sciences. MATERIALS : The MSCs derived from the healthy adult volunteers of marrow donors, plRES-EGFP-hVEGF165 containing total length of cDNA sequence of human VEGF165 gene was provided by Dr. Cheng Ting from Plastic Surgery Hospital of Peking Union Medical College. pSP65-hBMP2 containing total length of cDNA sequence of human BMP2 gene was provided by Dr. Guo Ximin from the Academy of Military Medical Sciences. Enkaryotic expression vector pIRESneo (Clontech Company) Pyrobest DNA Polymerae, restriction enzyme, DNA ligase and plasmid extraction kit, DNA Fragment Purification Kit (TaKaRa Company), LiorfectamineTM liposome transfection kit, DMEM medium, trypase, TRlzolRNA extraction kit (Gibco BRL), Omniscript RT kit (Qiagen), TaqplusDNA polymerase (Promega), PMSF, ieupeptin, aprotinin, chymostatin (Sigma), protease inhibitor, PVDF membrane (Amersham-Pharmacia Biotech), rabbit anti-human BMP2 antibody and VEGF monoclonal antibody (Santa Cruz Company), goat anti-rabbit IgG-peroxydase (Wuhan Boster), G418 (Ameresco Company in U.S). METHODS : The experiment was conducted in the Affiliated Hospital of Luzhou Medical College and the Plastic Surgery Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences betwe
关 键 词:骨形态发生蛋白质类 受体 血管内皮生长因子 基因 治疗学 骨髓 干细胞
分 类 号:R394.2[医药卫生—医学遗传学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...